Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Collaborative Medicinal Development LLC currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. This indicates a highly focused prosecution phase for the company's current pending matters.
The busiest examiner for the company is MARTIN, KEVIN STEPHEN, who is responsible for 1 pending office action. This 1 action constitutes the entire pending workload for the company. Since MARTIN, KEVIN STEPHEN is the only examiner listed, the outcome of the current prosecution depends on the interaction with this single official.
Practitioners should note that the concentration in 1 distinct art unit and with 1 distinct examiner allows for a very specific prosecution strategy. There is no complexity from multiple examiner styles or differing art unit standards. The company can focus entirely on the technical merits of the 1 pending office action and the feedback from MARTIN, KEVIN STEPHEN to move the application toward a resolution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.2% | +23.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155281 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | MARTIN, KEVIN STEPHEN | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18155281 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | MARTIN, KEVIN STEPHEN | 1624 | §103 | Final Rejection | 31d overdue | Pending | Jan 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial